For example, dose- and dose-intensity-related CSF pleocytosis was evident in clinical trials for tominersen in patients with Huntington’s disease (HD) [57,58] and also evident, though less so, in the tofersen trial in SOD1 ALS [59] and in early access programs for ASOs [60]. Here, SOD1 is linked to Huntington disease.